Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ION 839

Next Previous
X
Search
Drug Profile

ION 839

Alternative Names: AZD-2693; ION-839; IONIS-AZ6-2.5-LRx

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer AstraZeneca
  • Class Antisense oligonucleotides; Hepatoprotectants; Small molecules
  • Mechanism of Action Adiponutrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • No development reported Metabolic disorders

Most Recent Events

  • 05 Jun 2024 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial for Metabolic Disorders and Non-alcoholic Steatohepatitis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 15 Feb 2024 ION 839 is still in a phase I trial for Non-alcoholic steatohepatitis in USA (SC) (NCT04483947)
  • 18 Dec 2023 AstraZeneca completes a phase I trial for Non-alcoholic steatohepatitis in USA (SC) (NCT04483947)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top